Patent details

EP3316892 Title: NOVEL DOSAGE REGIMEN OF TIACUMICIN COMPOUND

The time of generation of the report may vary depending on the number of the selected files and the pages of each file. If the generation of the consolidated PDF file takes long, you may reduce the number of selected files and proceed with the generation of the PDF in batches.
You have not selected any documents

Unitary Effect

Unitary Effect Requested:
Yes
Unitary Effect Request Filing Date:
18/08/2023
Unitary Effect Status:
Unitary Effect Registered
Request Unitary Effect Accepted:
24/08/2023
Unitary Effect Date:
19/07/2023
Unitary Effect Registration Date:
24/08/2023
Request Unitary Effect Rejected:
Unitary Effect Re-establishment of rights Filing Date:
Unitary Effect Re-establishment of rights EPO Decision :
Unitary Effect Re-establishment of rights EPO Decision Date:
Unitary Effect Request Withdrawal Date:
Unitary Effect request has been accepted, please see the UPP register at the EPO for up-to-date information
UPP register:
EP3316892
SPC Number:
Creation Date:

Basic Information

Publication number:
EP3316892
WO Application Number:
EP2016001140
Type:
European Patent Granted for NL
Status:
Unitary Effect Registered
Publication Title:
Title When Made Available For Viewing:
Reason Lapsed:
Application number:
EP16756939.1
WO Publication Number:
WO2017005358
EPO Publication Language:
English
SPC Number:
First Applicant Residence Country:
Switzerland (CH)
Publications:

Dates

Filing date:
04/07/2016
Grant date:
19/07/2023
EP Publication Date:
09/05/2018
WO Publication Date:
12/01/2017
Claims Translations Received Date:
Claims Translation B1 Received Date:
Claims Translation B2 Received Date:
Claims Translation B3 Received Date:
Lapsed By Non Payment Annual Fee Date:
Renunciation Date:
NullificationDate:
Published:
Due To Cession Date:
Registration date:
19/07/2023
EP B1 Publication Date:
19/07/2023
EP B2 Publication Date:
EP B3 Publication Date:
Description Translation B1 Received Date:
Description Translation B2 Received Date:
Description Translation B3 Received Date:
Expiration date:
03/07/2036
Lapsed By Expiration Date:
Revocation Date:
Invalidity Date:
Response To Novelty Search Report Received:
Patent Granting Request:
Lapsed date:

Applicant/holder

From:
19/07/2023
 
 

 

Name:
Tillotts Pharma AG
Address:
Baslerstrasse 15, 4310 Rheinfelden, Switzerland (CH)

Inventor

1

Name:
KARAS, Andreas, Johannis
Address:
2333 BE Leiden, Netherlands (NL)

2

Name:
LONGSHAW, Christopher, Mark
Address:
2333 BE Leiden, Netherlands (NL)

3

Name:
DELGADO-HERRERA, Leticia
Address:
2333 BE Leiden, Netherlands (NL)

4

Name:
ZEIHER, Bernhardt, George
Address:
2333 BE Leiden, Netherlands (NL)

Priority

Priority Patent Number:
15075021
Priority Date:
03/07/2015
Priority Country:
European Patent Office (EPO) (EP)

Classification

IPC or IDT classification:
A61K 31/7048; A61P 31/04; A61P 1/12;

Publication

Bulletin

1

Bulletin Heading:
UP1
Journal edition number:
39/23
Publication date:
27/09/2023
Description:
European patents with registered Unitary Effect

2

Bulletin Heading:
EP2
Journal edition number:
29/23
Publication date:
19/07/2023
Description:
European patents granted for the Netherlands

European Patent Bulletin

1

Issue number:
202339
Publication date:
27/09/2023
Description:
Unitary Effect Request Receipt

2

Issue number:
202339
Publication date:
27/09/2023
Description:
Unitary Effect Request Acceptance

3

Issue number:
202329
Publication date:
19/07/2023
Description:
Grant (B1)

Annual Fee

Annual Fee(s) Due Date:
Annual Fee Number:
Last Annual Payment Date:
Last Annual Fee Paid Number:
Payer:
Filing date Document type Document Description Number of pages File Type